Methandienone (Metandienonum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Anabolics

Included in the formulation
АТХ:

A.14.A   Anabolic steroid drugs

Pharmacodynamics:

Stimulation of anabolic processes in tissues, reduction of catabolic processes,an increase in the production of erythropoietin, an increase in the concentration of inhibitor C-1 of the complement fraction, and a reduction in the content of C-2 and C-4 complement fractions.

Pharmacokinetics:

Quickly and completely absorbed in the gastrointestinal tract, low bioavailability due to the presence of the effect of "first passage" through the liver. Relationship with plasma proteins (specific globulin-carriers) 90%. It is subject to final metabolism in the liver with the formation of inactive metabolites. It is excreted by the kidneys.

Indications:

Cachexia of various etiologies; violation of protein metabolism (after severe injuries, surgeries, burns, radiation therapy); chronic infectious diseases with protein loss; progressive muscular dystrophy, HA-induced myopathy; diabetic angiopathy; the need to accelerate regeneration in fractures, injuries; slowing the growth of children (Shereshevsky-Turner syndrome, pituitary fascism); delay in puberty (sexual infantilism) and physical development in boys; encephalopathy on the background of alcoholic hepatitis.

ICD-10

IV.E20-E35.E30.0   Delayed puberty

IV.E20-E35.E34.3   Low-growth [dwarfism], not elsewhere classified

IV.E40-E46.E46   Protein-energy insufficiency, unspecified

VI.G70-G73.G71.0   Muscular dystrophy

VI.G70-G73.G72.0   Drug myopathy

VI.G90-G99.G92   Toxic encephalopathy

IX.I70-I79.I79.2 *   Peripheral angiopathy in diseases classified elsewhere

XVII.Q90-Q99.Q96   Turner syndrome

XVIII.R50-R69.R62   The absence of the expected normal physiological development

XVIII.R50-R69.R64   Cachexia

XIX.T08-T14.T14.20   Fracture in unspecified area of ​​body closed

XIX.T08-T14.T14.9   Injury, unspecified

Contraindications:

· Individual intolerance.

· Prostate cancer.

· Breast cancer (in men).

· Breast cancer (in women with hypercalcemia).

· Hypercalcemia.

· Severe hepatic insufficiency.

· Nephrosis.

· Glomerulonephritis (nephrotic stage).

· Pregnancy.

Carefully:

· Chronic heart failure, coronary atherosclerosis, myocardial infarction (including in the anamnesis).

· Diabetes.

· Hyperplasia of the prostate.

· Hepatic and / or renal insufficiency.

· Breast-feeding.

· Elderly age.

· Children and adolescence.

Pregnancy and lactation:

Action category for the fetus by FDA not determined. Contraindicated use during pregnancy and during breastfeeding.

Dosing and Administration:

Inside before meals in a dose of 5 mg 1-2 times a day.The maximum dose is 50 mg / day. The course of treatment is up to 4 weeks. Repeated course after 6-8 weeks.

Side effects:

Digestive system: nausea, vomiting, diarrhea, abdominal pain, impaired liver function, jaundice.

Blood: hypocoagulant state with a tendency to bleeding, leukemia, iron deficiency anemia.

Other: pain in tubular bones, the progression of atherosclerosis, peripheral edema.

Overdose:No data.
Interaction:

Strengthens the effect of anticoagulants, antiaggregants and hypoglycemic agents, as well as the side effects of hepatotoxic drugs.

Special instructions:

Children and adolescents after a 4-week course should take a break 1-2 months.

Instructions
Up